# +ND Capital

+ND Capital is a Private Equity based in Woodside, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Woodside, United States
- **Region:** North America
- **Address:** Woodside, CA, United States
- **Founded:** 2002
- **Assets under management:** >$800M (per the firm)
- **Website:** nd.capital
- **LinkedIn:** https://www.linkedin.com/company/nanodimension

## Regulatory record

- **Reports private funds:** No

## About

+ND Capital is a venture capital firm founded in 2002 that invests in life, physical, and data sciences. The firm invests across the United States and Europe through its teams in Silicon Valley, Switzerland, and the Cayman Islands. +ND Capital has over $500M under management and is currently investing its $335M third fund.

## Sectors

- Life Sciences
- Physical Sciences
- Data Sciences
- AI/ML
- Energy Transition & Renewables

## Offices

- Lausanne, Switzerland
- Grand Cayman, Cayman Islands

## People

- Aymeric Sallin — Founder & Chief Executive Officer
- Eric Moessinger — Partner
- Kirill Kuzmichev — Principal
- Gabriela Ecco — Principal
- Peter Liddiard — Chief Operating Officer & Chief Financial Officer
- Jonathan Nicholson — Executive Director of the General Partner
- Richard Coles — Director of the General Partner
- Alison Palmer — Vice President of the General Partner

## Questions

### Who runs investment decisions at +ND Capital?

Founder and CEO Aymeric Sallin leads the investment team and sits on boards including Crocus Technology, Natron Energy, H55, and Selecta Biosciences. Partner Eric Moessinger runs the life sciences practice from Silicon Valley, where he has led or sourced deals including Twis, Icosavax, and ARMO BioSciences. Principals Kirill Kuzmichev and Gabriela Ecco cover physical sciences and life sciences, respectively, with a venture-partner network of operating executives and former pharma C-suite leaders providing sector-specific diligence.

### How does +ND Capital source proprietary deal flow?

The firm's sourcing model relies on deep ties to European technical universities — especially EPFL, where Sallin is an active alumnus and board member — combined with a long-established transatlantic bridge to Silicon Valley. Several portfolio companies, including EVIR Therapeutics and Arctos Medical, were structured as university spin-outs. The firm also maintains a dense network of academic advisors such as EPFL Professor Emeritus André Châtelain and biophysicist Carl Pabo, giving it early line-of-sight into bench-level science before commercial formation.

### Which sectors does +ND Capital explicitly focus on, and which does it avoid?

The firm explicitly invests in life sciences, physical sciences, and data sciences — it defines its mandate as 'disruptive technologies' at the convergence of those disciplines. Current board companies include biopharma (AIRNA, Selecta Biosciences), advanced batteries (Natron Energy), semiconductors and edge AI (Crocus Technology, SiMa.ai), and electrified aviation (H55). The firm does not disclose explicit sectors it avoids, though its portfolio shows no recognizable exposure to consumer internet, enterprise SaaS, or financial services.

### How is the general partner entity at +ND Capital governed?

The general partner is overseen by a three-person Cayman Islands-based team: Jonathan Nicholson (Executive Director, former Managing Director of Merrill Lynch Bank & Trust Cayman), Richard Coles (Director, former Attorney General of the Cayman Islands), and Alison Palmer (Vice President, a chartered accountant and former PwC auditor). This governance layer is structurally separate from the investment team in Woodside and Lausanne and handles fund administration, regulatory compliance, and fiduciary duties.

## Related profiles

- [NDB Bank](https://altss.com/profile/ndb-bank)
- [NDI Medical](https://altss.com/profile/ndi-medical)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nd-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology